Skip to main content

Table 3 Acylcarnitine profile of the patient before and after riboflavin treatment

From: Patient with multiple acyl-CoA dehydrogenase deficiency disease and ETFDH mutations benefits from riboflavin therapy: a case report

Analytes

Results

Reference range

Units

Before

After

C0- Free carnitine

36

42

17–64

umol/L

C2- Acetylcarnitine

10

3

2-17

umol/L

C3-Propionylcarnitine

0.42

0.31

0.14–0.95

umol/L

C3DC-Malonylcarnitine

0.03

0.03

0.01–0.08

umol/L

C4-n-butyryl−/isobutyrylcarnitine

0.33

0.16

0.08–0.46

umol/L

C4OH-3-Hydroxy-Butyrylcarnitine

0.12

0.06

0.01–0.24

umol/L

C5-Isovaleryl−/2-Methylbutyrylcarnitine

0.39

0.10

0.03–0.32

umol/L

C5:1-Tiglylcarnitine

0.02

0.01

0.01–0.04

umol/L

C5OH-3-Hydroxy-Isovaerylcarnitine

0.03

0.03

0.01–0.09

umol/L

C5DC-Glutaryl/3-Hydroxydecanoylcarnitine

0.28

0.06

0.010.08

umol/L

C6-Hexanoylcarnitine

0.43

0.25

0.02–0.12

umol/L

C8-Octanoylcarnitine

1.50

1.69

0.03–0.22

umol/L

C10-Decanoylcarnitine

3.07

1.82

0.05–0.42

umol/L

C10:1-Decenoylcarnitine

0.40

0.61

0.03–0.26

umol/L

C10:2-Decadienoylcarnitine

0.05

0.05

0.01–0.05

umol/L

C12-Dodecanoylcarnitine

0.87

0.15

0.02–0.13

umol/L

C12:1-Dodecenoylcarnitine

0.13

0.09

0.01–0.10

umol/L

C14-Tetradecanoylcarnitine

0.51

0.05

0.01–0.07

umol/L

C14:1-Tetradecenoylcarnitine

0.72

0.15

0.01–0.17

umol/L

C14:2-Tetradecadienoylcarnitine

0.20

0.07

0.01–0.05

umol/L

C16-Hexadecanoylcarnitine

0.81

0.13

0.06–0.24

umol/L

C16:1-Hexadecenoylcarnitine

0.53

0.05

0.01–0.07

umol/L

C18-Octadecanoylcarnitine

0.34

0.04

0.02–0.10

umol/L

C18:1-Octadecenoylcarnitine

0.95

0.12

0.05–0.28

umol/L

C18:2-Linoleylcarnitine

0.33

0.05

0.02–0.10

umol/L

C16OH-3-Hydroxy-Hexadecanoylcarnitine

0.02

0.01

0.00–0.02

umol/L

  1. Numbers out of reference range are in bold